Introduction
Lenalidomide is an immunomodulatory drug (IMiD TM ) that has been studied extensively in non-Hodgkin lymphoma (NHL). There have been a multitude of pre-clinical and clinical studies that have helped define the role of lenalidomide in NHL.
Mechanisms of Action
The most prominent mechanisms of action of lenalidomide in lymphoid malignancies appear to be immunomodulatory, anti-proliferative, and anti-angiogenic ( Figure 1 ).
Immunomodulatory
Elegant pre-clinical studies showed that T-cell immune synapse dysfunction in follicular lymphoma (FL) can be "repaired" with lenalidomide. 1 Tumor-infiltrating T-cells from FL patients had significant reduction in formation of the F-actin immune synapse versus healthy donor cells. Lenalidomide reversed these abnormalities by enhancing the immune synapse, an important finding also demonstrated in chronic lymphocytic leukemia (CLL). 2 Additionally, lenalidomide has been shown to reduce Tregs, activate CD8 T-cells, and skew T-helper (T H ) subsets with T H1 > T H2 response. 3 In other NHL experiments, lenalidomide combined with rituximab resulted in antitumor effects via increased NK-cell function, enhanced antibody-dependent cellular cytotoxicity, improved NK-cell-mediated synapse formation, and CD20 capping. [4] [5] [6] [7] Further, Zhu et al reported that induction of apoptosis in Burkitt lymphoma (BL) and CLL cells occurred primarily through NK-cell activation. 
Anti-proliferative effects
A significant discovery in the mechanism of lenalidomide was identification of the 13, 14 Moreover, this effect was preferentially noted in non-germinal center (non-GC) DLBCL, which are more dependent on IRF4 and NF-κB than GC-DLBCL due to oncogenic mutations in CARD11 and MYD88. 13, 15 Cereblon has also been shown to be vital in lenalidomide-induced T-cell stimulation. 16 18 and CLL cells, the latter occurring in a cereblon-and p21-dependent, but p53-independent manner.
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Anti-angiogenic
Reddy et al showed that lenalidomide diminishes angiogenesis (decreased microvessel density (MVD)) in NHL xenograft models. 5 Related data in MCL mouse models revealed that lenalidomide inhibited tumor growth and dissemination by depleting monocytes and macrophages associated with lymphangiogenesis. 20 Lenalidomide has also been shown to up-regulate the tumor suppressor gene SPARC, which has antiproliferative, anti-adhesive, and anti-angiogenic properties in 5q-syndrome; 21 similar preliminary findings were noted in NHL, 22 though it's true importance remains to be validated.
Clinical Data
Phase I, II, and III clinical trials have defined the safety and efficacy of lenalidomide in several NHL subtypes including MCL, FL, DLBCL, and T-cell lymphoma ( Table 1) .
Mantle-cell lymphoma
Relapsed/refractory
In a single-agent study (NHL-002) 23 of relapsed/refractory aggressive NHL histologies, the overall response rate (ORR) of lenalidomide in MCL was 53% with 14% complete remission (CR) ( anemia). Grade 3 non-hematologic AEs included 7% fatigue, 6% diarrhea, 5%
dyspnea. These data led to FDA approval of lenalidomide June 2013 for MCL patients whose disease relapsed or progressed after two prior therapies, one of which included bortezomib.
In an update to MCL-001, median time to CR was 4.1 months and median overall survival (OS) was 20.9 months. 28 Dose reductions or interruptions due to AEs occurred in 40% and 58% of patients, respectively, and the average lenalidomide dose intensity was 20mg/day. Additionally, lower Ki67 levels (<30%) appeared to correlate with improved CR, DOR, and OS.
Untreated
There are ongoing clinical trials incorporating lenalidomide into treatment paradigms for untreated MCL (Supplemental Tables 1 and 2 ). Jerkeman et al 7 evaluated lenalidomide combined concurrently with bendamustine and rituximab (BR) in newly-diagnosed older MCL patients. 29 The phase 1 study identified an unexpected high rate of grade 3-4 allergic reactions and cutaneous toxicity and there were 3 treatment-related deaths ( Table 1) . The study was amended to omit lenalidomide from cycle 1 (i.e., starting cycle 2). Ruan et al presented data using lenalidomide combined with rituximab for first-line treatment of MCL. 30 Treatment was well tolerated with grade 3-4 toxicities of 39% neutropenia, 13% thrombocytopenia, 7%
anemia, 23% rash, and 7% tumor flare. Preliminary efficacy data were promising ( Table   1 ).
Follicular lymphoma
Relapsed/refractory disease NHL-001 documented the single-agent efficacy of lenalidomide for relapsed/refractory indolent NHL ( Table 1) ; 31 ORR was modest, however responding patients had durable remissions. Tuscano et al reported results with lenalidomide and rituximab in relapsed/refractory indolent NHL half of whom were rituximab-refractory ( Table   1) . 32 Additionally, UPenn published results of a carefully planned and well-done phase II study in rituximab-refractory FL and MCL showing that lenalidomide had activity as a singleagent and that lenalidomide/rituximab combination therapy may overcome rituximab resistance. 33 There is an ongoing phase III trial ("AUGMENT" study) evaluating lenalidomide combined with rituximab versus single-agent lenalidomide in relapsed/refractory indolent NHL (Supplemental Table 2 ).
Untreated patients
Fowler et al evaluated lenalidomide and rituximab in 110 untreated FL patients. 34 For personal use only. on August 31, 2017. by guest www.bloodjournal.org From 8
Responses were high, and at completion of therapy, most patients demonstrated molecular response. There are several ongoing randomized studies examining lenalidomide as part of front-line therapy for FL patients. This includes a randomized phase 2 study examining lenalidomide therapy following immuno-chemotherapy induction ("BIONIC" trial) and a phase 3 study comparing the efficacy of rituximab plus lenalidomide versus rituximab plus chemotherapy in untreated FL ("RELEVANCE" trial) (Supplemental Figure 1) .
DLBCL
Relapsed/refractory
Lenalidomide has activity in relapsed/refractory DLBCL ( Table 1) . In NHL-002 and NHL-003, the ORRs in DLBCL were 19% and 28%, respectively. 23, 35 The differential efficacy of lenalidomide in DLBCL based on cell of origin was evaluated by Hernandez et al; 36 lenalidomide appeared more effective in non-GC DLBCL with ORR of 53% versus 9% for GC subtype.
Zinzani et al reported data on 23 elderly DLBCL patients treated with rituximab and lenalidomide (with lenalidomide maintenance) 37 and Wang et al confirmed the clinical activity of lenalidomide/rituximab in relapsed/refractory de-novo and transformed DLBCL ( Table 1) . 38 Feldman et al studied the addition of lenalidomide to standard salvage chemotherapy for relapsed/refractory DLBCL prior to autologous stem cell transplantation followed by lenalidomide maintenance. 39 Ongoing studies are assessing lenalidomide combined with other chemotherapy backbones (Supplemental Table 2 ).
Untreated
The addition of lenalidomide to rituximab, cyclophosphamide, doxorubicin, oncovin, 9 and prednisone (R2-CHOP) was evaluated in older, untreated DLBCL patients ( Table   1) . 40 Efficacy appeared high, although ~70% of patients had grade 3-4 hematological
AEs. Nowakowski et al added modified lenalidomide to R-CHOP, which was well tolerated and it appeared to overcome the negative prognostic impact of non-GC phenotype in DLCBL. 41 A large, randomized phase II trial randomizing untreated DLBCL patients to R2-CHOP versus R-CHOP (Supplemental Figure 1) and a similarly designed industry-led study (only ABC-type DLBCL; ROBUST study), are underway.
The role of lenalidomide in the post-chemotherapy setting is also being investigated as maintenance therapy alone or combined with rituximab. Early results from a randomized phase II trial of lenalidomide +/-rituximab in intermediate-high/high risk DLBCL have been presented (Table 1) .
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T-cell lymphoma
Relapsed/refractory
The EXPECT phase II trial studied patients with relapsed/refractory peripheral Tcell lymphoma (PTCL) treated with single-agent lenalidomide ( Table 1) . 43 The majority of patients (85%) had angioimmunoblastic (AITL) and PTCL-not otherwise specified histologies. Efficacy was documented, though serious AEs were seen in 54% of patients with 6 deaths unrelated to progression. In additional single-agent studies, Tournishey et al reported results in untreated and relapsed/refractory PTCL, 44 while
Querfeld et al showed clinical activity in relapsed/refractory mycosis fungoides/sezary syndrome ( Table 1) . 45 In the latter study, tumor flare was seen in many patients, which prompted an amendment for lower initial lenalidomide dosing.
Untreated
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There are limited data examining lenalidomide in the front-line setting for PTCL.
A trial investigating the efficacy of lenalidomide combined with CHOP in AITL is ongoing and another study is evaluating romidepsin and lenalidomide in untreated PTCL (Supplemental Table 2 ).
Future Directions
Biomarkers
Clinical studies have examined potential biomarkers of lenalidomide efficacy 25, 33, 46 and pivotal studies are ongoing in distinct NHL subsets (e.g., non-GC DLBCL). In relapsed/refractory MCL, Zaja et al showed that MVD, macrophage and NK cell counts were altered with lenalidomide 46 and Ki67 is being studied as a biomarker. 28 Despite breakthrough studies that identified CRBN as a critical lenalidomide target, [9] [10] [11] [12] 47 there are challenges in utilization as a biomarker (e.g., messenger RNA/protein correlation). The CRBN-associated transcription factors, Ikaros/Aiolos, may serve as more functional biomarkers 16 as well as downstream substrates (e.g., IRF4 and MYC). Other potential lenalidomide-related biomarkers include components of PI3K signaling (e.g., GSK3β) 48 and the T-cell immune synapse with granzyme B expression.
49,50
Novel combinations
In DLBCL cells, azacytidine and lenalidomide increased CRBN expression and enhanced cytotoxicity 51 while iIbrutinib and lenalidomide synergistically suppressed IRF4. 13 In vitro FL and MCL studies confirmed synergistic activity with bortezomib and lenalidomide. 52 In T-cell lymphoma models, romidepsin combined with lenalidomide resulted in increased oxidative stress and alteration of PI3K and MAP kinase/ERK signaling pathways. 53 Conversely, preclinical studies in CLL suggests that the PI3Kδ 11 inhibitor, idelalisib, antagonizes the immune-modulating properties of lenalidomide.
It will be important to translate these findings in clinical studies to confirm efficacy as well as safety. The latter was highlighted in two phase I studies combining lenalidomide with the PI3Kδ inhibitor, idelalisbub, (and rituximab) where prohibitive toxicities suggestive of severe cytokine release syndrome (e.g., rash, fevers, hypotension) were seen.
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Other clinical studies combining lenalidomide with novel/targeted agents have shown good tolerability and encouraging efficacy, 55 while additional novel combinatorial trials are underway (e.g., obinutuzumab, romidepsin, everolimus, ibruitinib) (Supplemental Table   2 ).
In addition, translational study of new cereblon binding agents (e.g., CC-122) are eagerly anticipated. 56 CC-122 is a first-in-class, pleiotropic pathway modifier that binds cereblon and induces Aiolos and Ikaros degradation in DLBCL and T-cells. 57 In DLBCL, it results in depression of interferon-stimulated genes/proteins ultimately resulting in apoptosis. 58 Furthermore, CC-122 appears to have distinct activity from lenalidomide in that it is active in both GC and non-GC DLBCL.
56,58
Conclusions
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